Pharma Mirror

MAY 19, 2021

Azbil Telstar announces the appointment of Rashedi Hassan as a Sales & Marketing Manager of the subsidiary of the company in Dhaka, Bangladesh. The post Rashedi Hassan takes over Sales & Marketing management of Telstar’s subsidiary in Bangladesh appeared first on Pharma Mirror Magazine. With more than 18.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies 98

PharmExec

DECEMBER 22, 2022

Pratap Khedkar, CEO of ZS, a management consulting and technology firm focused on transforming global healthcare, shares his perspective on what 2023 holds for the sales and marketing vertical.

52

52

Pharma Mirror

OCTOBER 17, 2022

The post Artificial Intelligence (AI) in Pharma Sales and Marketing appeared first on Pharma Mirror Magazine. This could be used to determine target audiences, decide on optimal times to send emails, or segment out groupings for deeper engagement. Deep learning In.

52

52

Fierce Pharma

APRIL 23, 2024

The orphan drug sector has long been clearing growth in the larger pharmaceutical market with booming sales. | The orphan drug sector has long been clearing growth in the larger pharmaceutical market with booming sales.

129

129

Mission-Driven Marketing Blog

APRIL 5, 2021

Inbound Marketing, a methodology which seeks to attract leads through generating valuable content and experiences, has been outpacing traditional forms of marketing, like Outbound Marketing or ‘Push’ Marketing, in recent years.

52

52

Pharma Mirror

APRIL 14, 2021

The role of pharma sales reps is an incredibly important part of this lifecycle from initial research to point of sale and distribution, with reps connecting the groundbreaking research and technology of pharma companies with healthcare professionals and medical establishments.

52

52

PhRMA

JUNE 14, 2023

The 340B Drug Pricing Program has grown yet again , exceeding $100 billion in sales in 2022 when 340B-priced medicines are measured at wholesale acquisition cost. year-over-year in 2022, continuing a trend in which 340B sales have almost doubled since 2018, outpacing growth of the total U.S. drug market.

261

261

PharmExec

AUGUST 23, 2023

Program designed to aid life science organizations in improving go-to-market strategy.

98

98

Fierce Pharma

AUGUST 3, 2023

Even as Moderna chugs through another post-pandemic year, the biotech has raised its COVID-19 vaccine revenue projection in the expectation that it can deliver a strong showing in the private marke | The company raised its forecast for COVID-19 sales to between $6 billion and $8 billion, up from a prior estimate of $5 billion.

Vaccines 98

Vaccines 98

Fierce Pharma

APRIL 5, 2024

Despite Boehringer Ingelheim’s 2021 Humira biosimilar approval being heralded by some analysts as a “landmark achievement” for the field, the drug—dubbed Cyltezo—has struggled to gain traction than | Facing lackluster Cyltezo sales, Boehringer Ingelheim will prune its ranks in the U.S.

121

121

Fierce Pharma

MARCH 22, 2024

Sales are booming for Novo Nordisk’s GLP-1 treatments for diabetes and obesity. With a positive recommendation from Europe’s Committee for Medicinal Products for Human Use (CHMP), Novo has come a step closer to bringing its revolutionary Awiqli (once weekly basal insulin icodec) to the market. .

128

128

Fierce Pharma

JANUARY 10, 2024

Despite persistent supply hitches since Wegovy’s launch in 2021, Novo Nordisk has quickly garnered blockbuster sales in the newly untapped obesity market. Despite persistent supply hitches since Wegovy’s launch in 2021, Novo Nordisk has quickly garnered blockbuster sales in the newly untapped obesity market.

98

98

Fierce Healthcare

AUGUST 10, 2023

Primary care company Cano Health is exploring a sale as its cash dwindles and plans to lay off 700 employees, or 17% of its workforce, the company announced Thursday. Primary care company Cano Health is exploring a sale as its cash dwindles and plans to lay off 700 employees, or 17% of its workforce, the company announced Thursday.

76

76

Pharmaceutical Commerce

AUGUST 24, 2023

Program designed to aid life science organizations in improving go-to-market strategy.

52

52

pharmaphorum

JANUARY 3, 2024

This article explores the efficacy, potential sales, and market trends in the field of obesity drugs. The race for obesity drug assets is becoming more intense as pharmaceutical companies strive to develop effective treatments for weight loss.

Pharmaceutical Companies 118

Pharmaceutical Companies Pharmaceutical Companies 118

Drug Topics

NOVEMBER 10, 2023

Stephen Barnes, BA, MA, director of sales and marketing at BestRx Pharmacy Software, discussed the ways that software can optimize a pharmacy's revenue.

98

98

Pharmafile

FEBRUARY 10, 2023

AbbVie Inc has announced that it expects to see a 37% decline in sales of its flagship rheumatoid arthritis drug Humira, as new competition emerges in the form of cheaper biosimilar drugs. The company expects its sales to stabilise by the end of 2024. read more

52

52

Fierce Pharma

JANUARY 3, 2024

Expect more of the same in 2024, according to a report from Evaluate, which places Novo and Lilly in the top two spots for global new sales. Expect more of the same in 2024, according to a report from Evaluate, which places Novo and Lilly in the top two spots for global new sales.

127

127

pharmaphorum

FEBRUARY 7, 2024

GSK has revealed the data it hopes will allow a return to the US market for Blenrep, which was the first BCMA-targeting drug to launch there but was withdrawn from sale after it failed a confirmatory trial.

105

105

Drug Topics

SEPTEMBER 13, 2023

Matthew Lee, vice president of sales and marketing at MedOne, led a discussion about trends in care management from a PBM and health perspective.

112

112

PhRMA

MARCH 30, 2023

Part B uses a unique payment mechanism known as average sales price (ASP) to calculate the price of most of the wide range of medicines it covers. ASP takes into account commercial market negotiation to save the government and seniors money. Why is it so unique?

202

202

Fierce Pharma

SEPTEMBER 7, 2023

Demand is so strong for Novo Nordisk’s obesity drugs that the only limitation on sales—in the short term—seems to be the company’s ability to produce them. Morgan, which has doubled its market projection for GLP-1 diabetes and obesity treatments to $71 billion for 2032.

139

139

Pharma Times

SEPTEMBER 10, 2021

The entry deadline for the 2021 Marketer of the Year, Sales and Communications Awards has been extended to 22nd of October

Communication 32

Communication 32

STAT

MARCH 8, 2024

But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS.

FDA 145

FDA 145

STAT

APRIL 4, 2024

WASHINGTON —  Boehringer Ingelheim is laying off or relocating its sales staff for its Humira biosimilar Cyltezo in a sign of how difficult it’s been to get drug middlemen to adopt less-expensive versions of the blockbuster, the company confirmed. After two decades on the U.S.

140

140

Fierce Pharma

DECEMBER 20, 2023

Last year, reports surfaced that Novartis—hot off the heels of a planned restructuring and spinoff of generics giant Sandoz—was further weighing a sale for its ophthalmology business. | The sale is expected to go into effect in January 2027. plans to distribute and market the medicines in India. Chemicals & Pharmaceuticals.

98

98

Fierce Pharma

NOVEMBER 2, 2023

Roche’s surge in sales for its long-acting macular degeneration drug Vabysmo showed that patients in the market are open to switching to another treatment. After gaining FDA approval for its high-dose Eylea, Regeneron racked up $43 million in sales in the U.S.

FDA 106

FDA 106

Fierce Pharma

OCTOBER 30, 2023

As sales of their GLP-1 diabetes and obesity drugs have surged, Eli Lilly and Novo Nordisk have become the most valuable biopharma companies in the United States and Europe, respectively. That didn | It was no surprise that GLP-1 drugmakers Eli Lilly and Novo Nordisk saw market-cap gains of 16.1% in the third quarter.

118

118

Digital Pharmacist

JULY 31, 2023

To boost your pharmacy’s storefront sales, the best place to start is by understanding the importance of pharmacy marketing and making sure you are taking the necessary steps to optimize your front-end sales. By following these tips, you can take your pharmacy’s front-end sales to the next level.

Communication 98

Communication 98

European Pharmaceutical Review

OCTOBER 12, 2023

Strong demand for small molecules as treatment for non-small cell lung cancer (NSCLC) in the eight major markets means that the small molecule treatment market for the disease is expected to reach over $15 billion by 2029. This represents approximately 40 percent of the total NSCLC market, stated GlobalData. percent by 2029.

FDA 89

FDA 89

PharmExec

SEPTEMBER 9, 2022

Senior leaders in pharma, healthcare marketing and communications, and advertising got together to discuss the progress and lingering roadblocks in advancing diversity, equity, and inclusion strategies in the life sciences—where the common thread seems clear: the messenger matters.

Communication 52

Communication 52

Fierce Pharma

JULY 26, 2023

Expectations are sky high for GSK’s entry this fall into the new respiratory syncytial virus (RSV) vaccine market. | In a quarter fueled by sales of Shingrix and its HIV medicines, GSK topped revenue expectations and bumped up its sales projection for the year.

Vaccines 94

Vaccines 94

STAT

APRIL 25, 2024

The need-to-know this morning AstraZeneca reported first-quarter  sales and profits  that topped analyst estimates, buoyed by its blockbuster cancer drugs. It’s a busy day for pharma earnings:  Merck ,  Sanofi ,  Daiichi Sankyo ,  Astellas , and  Bristol Myers Squibb.

Hospitals 94

Hospitals 94

Drug Store News

FEBRUARY 23, 2023

Despite continued market share gains in sales of both consumable and non-consumable products, same-store sales for the fourth quarter increased by 5.7%.

97

97

STAT

APRIL 11, 2024

The European Parliament has voted overwhelmingly to adopt legislation that is supposed to transform the way medicines are brought to market and accessed across much of Europe. But the effort — which must still be approved by the European Council — drew mixed reactions from the pharmaceutical industry and consumer groups.

124

124

Fierce Pharma

SEPTEMBER 13, 2023

. | Moderna CEO Stéphane Bancel is optimistic that the company will beat the low end of its $6 billion to $8 billion COVID vaccine sales estimate for 2023. But his optimism comes as Moderna reportedly eyes manufacturing cuts as it shifts to an endemic market response.

Vaccines 120

Vaccines 120

Pharmaceutical Technology

SEPTEMBER 1, 2023

As per GlobalData, AbbVie has remained the Crohn’s disease market leader over the last five years, with Humira sales of $2.7bn in 2022 in 8MM.

98

98